Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma

Next Previous
Trial Profile

A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clofarabine (Primary) ; Mitoxantrone (Primary) ; Cytarabine; Dexrazoxane; Rituximab
  • Indications Acute myeloid leukaemia; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Acronyms MITCL

Most Recent Events

  • 13 Dec 2022 Results assessing the safety, overall response rate and long term EFS/OS in a Phase I/II trial of clofarabine in combination with mitoxantrone as reinduction therapy for relapsed or refractory pediatric acute leukemia, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 24 Oct 2022 Status changed from active, no longer recruiting to completed.
  • 29 Oct 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top